Skip to content

VRTX

Vertex Pharmaceuticals Incorporated

Revenue by product

2025, ended Dec 31, 2025

Earlier:

Products by fiscal year

Products by fiscal year
Line, in USD2025202420232022202120202019201820172016
Trikafta/kaftrio10.3B10.2B8.9B7.7B5.7B3.9B420M———
Alyftrek838M—————————
Other CF product revenues0.82B0.78B0.92B1.24B——————
Product revenues, net12.0B———7.6B6.2B4.2B3.0B——
Kalydeco
————0.68B0.80B0.99B1.01B0.84B0.70B
Orkambi
————0.77B0.91B1.33B1.26B1.32B0.98B
Symdeko/symkevi
————0.42B0.63B1.42B0.77B——
Other revenues31M———1.0M2.9M2.1M9.3M323M19M
Earlier
Other—————————610K
Total12.0B11.0B9.9B8.9B7.6B6.2B4.2B3.0B2.5B1.7B